A Case Study Series to Evaluate the Safety and Efficacy of a Novel Keratolytic in Patients 
Diagnosed with Plaque Psoriasis

Tien Q. Nguyen, M.D., Andrea Nguyen, MS, PA-C

First O C Dermatology, Fountain Valley, CA

Background
Many patients with plaque psoriasis suffer from
noticeable physical disease aff liction. Globally, the
prevalence of psoriasis reported in population-
based studies in adults ranges from 1% to 8.5%,
with differences based on geographic location.1
Treatment can be burdensome and includes
Keratolytics for scale and plaques reduction. A
new treatment for plaque psoriasis, which aids in
the gentle physical removal of the scale has been
developed with the purpose of removing scale
without causing irritation, spot bleeding and
infection.

LOYON® (PB/LO-112) is a unique, patented
combination of the dry emollient Cetiol® CC and
the medical silicone oil dimethicone. The
combination of the 2 substances gives LOYON® a
low surface tension as well as high creep and
spreading properties. The liquid is very easily
applied and allows a gentle yet effective lifting of
scales.

This study evaluated the safety and effectiveness
of LOYON® in treating plaque and scaling buildup
in patients diagnosed with plaque psoriasis.

Results

All 8 patients completed the study and showed 
improvement of their scaling with a 43% overall 
reduction.  Overall, PASI scores improved by 19% 
upon completion of treatment. There were no 
adverse events reported and most of the patients 
stated that they were satisfied with the performance 
of the study medication on their plaque psoriasis.

Conclusions
LOYON® improved scaling in patients with plaque 
psoriasis and had a favorable safety profile. 
Additionally, patients were pleased with the 
performance of this novel keratolytic.

Reference

Objectives

Methods
Eight patients were enrolled in this open label
study. Each had a diagnosis of plaque psoriasis with
scaling. There were 2 study visits—Visit 1 (Baseline)
and Visit 2 (end of study visit).
During the study period, patients were asked to
refrain from using any other products to treat their
plaque psoriasis. Pictures of a designated target area
of the subjects’ plaque psoriasis were taken at each
visit. At each visit the study investigator rated the
patient’s Psoriasis Area Severity Index and overall
Investigator’s Global Assessment. Evaluation of
treatment results ranged from live assessment (by
the investigator) to photographic assessment.
Patients received Loyon® study medication at Visit 1
and were instructed how to apply Loyon® onto dry
skin and gently massage it into the skin. Patients
were asked to leave medication on the skin for at
least 3 hours before washing it off with a mild
cleanser and/or shampoo. Patients applied
medication twice a day for 7 consecutive days, and
up to an additional 7 consecutive days if needed for
patients with more severe scales.

Patient with plaque psoriasis on the elbow at Visit 1 
(A) and Visit 2 (B)

A

B

Patient with plaque psoriasis on the forehead at 
Visit 1 (A) and Visit 2 (B)

A

B

Patient with plaque psoriasis of the hand at Visit 1 
(A) and Visit 2 (B)

1. Michalek IM, Loring B, John SM. A systematic review 
of worldwide epidemiology of psoriasis J Eur Acad
Dermatol Venereol. 2017;31(2):205.

A

B

Patients completed a diary capturing their
application compliance. Additionally, they were
asked to complete a one-page survey to determine
their evaluation and compliance of the study
medication.


	FC17PosterIntraDermNguyenACaseStudySeries.pdf